Sobi posts 61% increase in 2016 revenues

17 February 2017

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has announced its results for the fourth quarter and full year 2016. Revenues for the full year totalled 5,204 million Swedish kronor ($584.7 million), an increase of 61% compared to 2015.

Revenues for the quarter were 1,292 million kronor, an increase of 59%. Product sales for the full year amounted to 4,548 million kronor, an increase of 77%, based on strong performance across the portfolio and the launch of our new hemophilia products, Elocta (efmoroctocog alfa) and Alprolix (coagulation Factor IX [recombinant], Fc fusion protein).

Gross margin for the quarter was 67%, compared with 64% in the like 2015 quarter. Earnings before tax and amortization were 210 million kronor versus 90 million kronor, with earnings per share of 0.37 kronor (-0.04)

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK